16th November 2020
The patent landscape behind the Nobel Prize awarded to CRISPR
The 2020 Nobel Prize in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier in October for their work on the gene editing tool CRISPR/Cas 9, commonly referred to as CRISPR.
This Nobel Prize does not come without some controversy. Not only are the winners involved in a patent dispute relating to CRISPR, where Doudna’s and Charpentier’s interests are represented by the University of California while Feng Zhang, on the other side of the patent dispute, is active at The Broad Institute of MIT and Harvard and was notably not included in the award by the Nobel committee.
We have looked into the patents behind the CRISPR technology and discovered who the key players are in this space and how this is impacting the patent landscape.
Our article explores some of the following key findings:
- The potential of CRISPR is undisputed, but who controls the patent assets?
- Although universities are still in control of some of the largest patent portfolios relating to the CRISPR tool, commercial organisations are actively using and patenting this technology.
- DuPont De Nemours and Regeneron Pharmaceuticals have comparatively small portfolios, but they are equally as important to the Harvard, MIT and Broad Institute portfolios.
Download the full article by filling out the form below.
‘CRISPR Nobel Prize’ PDF Download
CRISPR NOBEL PRIZE
Gain an insight into the companies behind this growing area of innovation
The report looks at the following areas:
- key patent asset holders of the CRISPR technology
- the evolving CRISPR patent landscape
- the future of CRISPR as patent disputes are ongoing